Related Experiment Videos
[Anti-platelet agents in peripheral vascular surgery].
H Van Damme1, J L David, R Limet
1Service de Chirurgie cardio-vasculaire, Université de Liège.
Revue Medicale De Liege
|April 30, 1999
Summary
Platelet inhibitors significantly improve arterial reconstruction patency by reducing graft thrombosis and intimal hyperplasia. These antiplatelet drugs also offer secondary prevention benefits for cardiovascular events in high-risk patients.
Area of Science:
- Vascular Surgery
- Pharmacology
- Cardiovascular Medicine
Context:
- Graft failure and arterial thrombosis are major concerns in vascular surgery.
- Non-thromboresistant grafts and intimal injury contribute to graft failure.
- Platelet adhesion and intimal hyperplasia are key pathological processes.
Purpose:
- To review platelet function and inhibitors (aspirin, dipyridamole, ticlopidine).
- To discuss the pathophysiology of intimal hyperplasia.
- To evaluate the role of antiplatelet therapy in arterial reconstructions.
Summary:
- Platelet inhibitors reduce early graft failure by 50%, lowering one-year thrombosis rates from 40% to 20%.
- Antiplatelet drugs slow atherosclerotic progression in outflow vessels.
- For polyvascular patients, these drugs reduce myocardial or cerebral infarction risk by 30%.
Impact:
- Antiplatelet therapy is beneficial for early and late patency of peripheral vascular reconstructions.
- Consistent use of platelet inhibitors improves outcomes in carotid endarterectomy, bypass grafts, and endovascular procedures.
- Platelet inhibitors are crucial for managing patients with polyvascular disease, enhancing secondary prevention.